Search Results - "GOEDEGEBUURE, Peter"

Personalized cancer vaccines: Targeting the cancer mutanome by Zhang, Xiuli, Sharma, Piyush K, Peter Goedegebuure, S, Gillanders, William E

“…Highlights • Next generation sequencing technologies can identify candidate neoantigens in different types of cancers. • Neoantigens can be recognized by the…”
Get full text

Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids by Shirure, Venktesh S, Bi, Ye, Curtis, Matthew B, Lezia, Andrew, Goedegebuure, Madeleine M, Goedegebuure, S Peter, Aft, Rebecca, Fields, Ryan C, George, Steven C

“…Most cancer treatment strategies target cell proliferation, angiogenesis, migration, and intravasation of tumor cells in an attempt to limit tumor growth and…”
Get more information

Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression by Silva-Fisher, Jessica M., Dang, Ha X., White, Nicole M., Strand, Matthew S., Krasnick, Bradley A., Rozycki, Emily B., Jeffers, Gejae G. L., Grossman, Julie G., Highkin, Maureen K., Tang, Cynthia, Cabanski, Christopher R., Eteleeb, Abdallah, Mudd, Jacqueline, Goedegebuure, S. Peter, Luo, Jingqin, Mardis, Elaine R., Wilson, Richard K., Ley, Timothy J., Lockhart, Albert C., Fields, Ryan C., Maher, Christopher A.

“…Colorectal cancer (CRC) is the most common gastrointestinal malignancy in the U.S.A. and approximately 50% of patients develop metastatic disease (mCRC)…”
Get full text

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses by MITCHEM, Jonathan B, BRENNAN, Donal J, HEWITT, Stephen, MALLYA UDUPI, Girish, GALLAGHER, William M, WEGNER, Craig, WEST, Brian L, WANG-GILLAM, Andrea, GOEDEGEBUURE, Peter, LINEHAN, David C, DENARDO, David G, KNOLHOFF, Brett L, BELT, Brian A, YU ZHU, SANFORD, Dominic E, BELAYGOROD, Larisa, CARPENTER, Danielle, COLLINS, Lynne, PIWNICA-WORMS, David

“…Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in aggressive tumors. Consequently, the type and quality of immune responses…”
Get full text

Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer by Gonzalez-Pastor, Rebeca, Goedegebuure, Peter S., Curiel, David T.

“…Ovarian cancer is the leading cause of death among women with gynecological cancer, with an overall 5-year survival rate below 50% due to a lack of specific…”
Get full text

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis by SANFORD, Dominic E, BELT, Brian A, WANG-GILLAM, Andrea, EBERLEIN, Timothy J, DENARDO, David G, GOEDEGEBUURE, Simon Peter, LINEHAN, David C, PANNI, Roheena Z, MAYER, Allese, DESHPANDE, Anjali D, CARPENTER, Danielle, MITCHEM, Jonathan B, PLAMBECK-SUESS, Stacey M, WORLEY, Lori A, GOETZ, Brian D

“…To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer…”
Get full text

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial by Nywening, Timothy M, MD, Wang-Gillam, Andrea, MD, Sanford, Dominic E, MD, Belt, Brian A, MA, Panni, Roheena Z, MD, Cusworth, Brian M, BA, Toriola, Adetunji T, MD, Nieman, Rebecca K, MS, Worley, Lori A, BS, Yano, Motoyo, MD, Fowler, Kathryn J, MD, Lockhart, A Craig, MD, Suresh, Rama, MD, Tan, Benjamin R, MD, Lim, Kian-Huat, MD, Fields, Ryan C, MD, Strasberg, Steven M, Prof, Hawkins, William G, Prof, DeNardo, David G, PhD, Goedegebuure, S Peter, PhD, Linehan, David C, Dr Prof

“…Summary Background In pancreatic ductal adenocarcinoma, the CCL2–CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an…”
Get full text

T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer by Washburn, Michael L, Wang, Zhang, Walton, Andrew H, Goedegebuure, S Peter, Figueroa, David J, Van Horn, Stephanie, Grossman, Julie, Remlinger, Katja, Madsen, Heather, Brown, James, Srinivasan, Roopa, Wolf, Amaya I, Berger, Scott B, Yi, Victoria N, Hawkins, William G, Fields, Ryan C, Hotchkiss, Richard S

“…Sepsis is characterized as life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The purpose of this investigation was…”
Get full text

Cancer vaccines: shared tumor antigens return to the spotlight by Li, Lijin, Goedegebuure, S. Peter, Gillanders, William

Get full text

Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer by Panni, Roheena Z., Sanford, Dominic E., Belt, Brian A., Mitchem, Jonathan B., Worley, Lori A., Goetz, Brian D., Mukherjee, Pinku, Wang-Gillam, Andrea, Link, Daniel C., DeNardo, David G., Goedegebuure, S. Peter, Linehan, David C.

“…Pancreatic cancer (PC) mobilizes myeloid cells from the bone marrow to the tumor where they promote tumor growth and proliferation. Cancer stem cells (CSCs)…”
Get full text

sc2MeNetDrug: A computational tool to uncover inter-cell signaling targets and identify relevant drugs based on single cell RNA-seq data by Feng, Jiarui, Goedegebuure, S Peter, Zeng, Amanda, Bi, Ye, Wang, Ting, Payne, Philip, Ding, Li, DeNardo, David, Hawkins, William, Fields, Ryan C, Li, Fuhai

“…Single-cell RNA sequencing (scRNA-seq) is a powerful technology to investigate the transcriptional programs in stromal, immune, and disease cells, like tumor…”
Get full text

Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Tan, Marcus C. B, Goedegebuure, Peter S, Belt, Brian A, Flaherty, Brian, Sankpal, Narendra, Gillanders, William E, Eberlein, Timothy J, Hsieh, Chyi-Song, Linehan, David C

“…Tumors evade immune destruction by actively inducing immune tolerance through the recruitment of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg). We have…”
Get full text

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles by Strand, Matthew S, Krasnick, Bradley A, Pan, Hua, Zhang, Xiuli, Bi, Ye, Brooks, Candace, Wetzel, Christopher, Sankpal, Narendra, Fleming, Timothy, Goedegebuure, S Peter, DeNardo, David G, Gillanders, William E, Hawkins, William G, Wickline, Samuel A, Fields, Ryan C

“…Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS…”
Get full text

The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer by Hagi, Takaomi, Vangveravong, Suwanna, Takchi, Rony, Gong, Qingqing, Goedegebuure, S. Peter, Tiriac, Herve, Van Tine, Brian A., Powell, Matthew A., Hawkins, William G., Spitzer, Dirk

“…Cancer selective apoptosis remains a therapeutic challenge and off-target toxicity has limited enthusiasm for this target clinically. Sigma-2 ligands (S2) have…”
Get full text

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth by Porembka, Matthew R., Mitchem, Jonathan B., Belt, Brian A., Hsieh, Chyi-Song, Lee, Hyang-Mi, Herndon, John, Gillanders, William E., Linehan, David C., Goedegebuure, Peter

“…Purpose Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immunosuppressive cells that are upregulated in cancer. Little is known about…”
Get full text

Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer by Grossman, Julie G, Nywening, Timothy M, Belt, Brian A, Panni, Roheena Z, Krasnick, Bradley A, DeNardo, David G, Hawkins, William G, Goedegebuure, S Peter, Linehan, David C, Fields, Ryan C

“…The tumor microenvironment (TME) represents a significant barrier to creating effective therapies for metastatic colorectal cancer (mCRC). In several…”
Get full text

Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation by Li, Lijin, Zhang, Xiuli, Wang, Xiaoli, Kim, Samuel W, Herndon, John M, Becker-Hapak, Michelle K, Carreno, Beatriz M, Myers, Nancy B, Sturmoski, Mark A, McLellan, Michael D, Miller, Christopher A, Johanns, Tanner M, Tan, Benjamin R, Dunn, Gavin P, Fleming, Timothy P, Hansen, Ted H, Goedegebuure, S Peter, Gillanders, William E

“…Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized…”
Get full text

Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation by Geng, Kexin, Rice-Boucher, Paul J, Kashentseva, Elena A, Dmitriev, Igor P, Lu, Zhi Hong, Goedegebuure, S Peter, Gillanders, William E, Curiel, David T

“…mRNA vaccines have attracted widespread research attention with clear advantages in terms of molecular flexibility, rapid development, and potential for…”
Get full text

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer by Peng, Hui, Li, Lijin, Zuo, Chong, Chen, Michael Y, Zhang, Xiuli, Myers, Nancy B, Hogg, Graham D, DeNardo, David G, Goedegebuure, S Peter, Hawkins, William G, Gillanders, William E

“…Cancer neoantigens are important targets of cancer immunotherapy and neoantigen vaccines are currently in development in pancreatic ductal adenocarcinoma…”
Get full text

pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection by Xia, Huiming, Hoang, My H, Schmidt, Evelyn, Kiwala, Susanna, McMichael, Joshua, Skidmore, Zachary L, Fisk, Bryan, Song, Jonathan J, Hundal, Jasreet, Mooney, Thomas, Walker, Jason R, Goedegebuure, S. Peter, Miller, Christopher A, Gillanders, William E, Griffith, Obi L, Griffith, Malachi

“…Background Neoantigen-targeting therapies including personalized vaccines have shown promise in the treatment of cancers, particularly when used in combination…”
Get full text